Connbey rebuked the heavy gold stake Jia and biological good chess or stink chess

Since the beginning of this year, the global market at first biopharmaceutical market, the relevant targets are hot, this market competition is becoming increasingly fierce. Unicorn drug Mingkangde in the A-share listing, ushered in four ups and downs, the market value quickly rose to 47.442 billion yuan (as of 10 a.m. on May 14); Even if the target is not yet profitable, it is still favored by investors when the trend is obvious. Among them, Chinese medicine enterprises Conebe high premium participation in biopharmaceus research and development enterprises Jia and bio is a typical.value-added rate of net assets is as high as 590%
on the evening of May 10, Watson Bio (300142. According to SZ), the company's controlling subsidiary Jiahe Bio-other shareholders Sunshine Life Insurance Co., Ltd. (called Sunshine Life), Beijing Sunshine Fusion Medical and Health Industry Growth Investment Management Center (Limited Partnership) (called Sunshine Convergence), Shihezi Ansheng Investment Partnership (Limited Partnership) (Aceh Investment) intends to transfer its stake in Jiahe Bio, the company intends to give up the right to purchase priority.
In accordance with the overall valuation of Jia and Bio 3.1 billion yuan, Sunshine Life and Sunshine Fusion intend to transfer their respective stakes of Jia and Bio 15.79 percent and 5.26 percent to Kang enbe (600572. SH), Ansheng Investment intends to transfer Jia and Bio's 5.22% stake for nearly 162 million yuan to Fujian Pingtan Huaxing Kangping Pharmaceutical Industry Investment Partnership (Limited Partnership). Upon completion of the share transfer, Watson Bio still holds a 68.47 per cent stake in Jia and Bio and remains the controlling shareholder of Jia and Bio, with Conebey becoming the second largest shareholder with a 21.05 per cent stake in Jia and Bio.
note that the target of this transfer has a higher premium. As of the end of the first quarter of this year, Jia and Bio's total assets of 661 million yuan, net assets of 449 million yuan, and Jia and Bio's overall valuation of 3.1 billion yuan, compared with the aforementioned net asset size appreciation rate of up to 590%. And, judging by Watson Bio's announcement, Jia and Bio have not been profitable since its inception in December 2007. In the first quarter of 2018, Jiayu Bio had no revenue and a net profit loss of RMB11.8015 million, which may have been an important factor in Watson Bio's waiver of its preferred right to purchase.
, what is the charm of burning tens of millions of jia and creatures every year that makes Connbey want to take a stake at a high premium?
Kang Enbei said that the company has not been able to build a complete platform for biopharmaceus research and development, process, industrial production, can not support and meet the company's strategic positioning and next development of the biopharmaceus industry. The investment will provide opportunities and conditions for Conebey to enter the biopharmaceus industry, in line with the company's strategic development needs. At the same time, according to the current clinical progress of Jia and Bio, there is a possibility of 2-3 large varieties being approved for listing in the next 3 years. The company is expected to invest in the next 2-3 years for the company's marketing network system to provide biological drug varieties of resources, for the company's prescription drug marketing network system to further strengthen and provide opportunities and conditions.jia and bio-competitiveness
jia and bio-technology since its infested in 2007, its research products include two categories: biosimilars and mono-anti-innovative drugs (NMEs), the latter mainly in fast-follow-up drugs (Fast-followers) and biobetters." Major adaptive disorders include major diseases such as tumors, autoimmune diseases and metabolic diseases. At present, Jia and biological project development focus on research and development of single anti-products have 10, of which 8 products have been approved for domestic clinical trials, clinical trials are under way (including 3 Phase III. trial products), another product in the clinical review process, 1 product in the domestic application for clinical withdrawal, and a number of other products are also synchronized in foreign countries such as Australia and South Korea clinical trials.
addition to the research and development pipeline, Jiahe Bio owns 16 patents that have been granted and intangible assets of 11 registered trademarks at home and abroad.
2016, domestic biopharmaceons sales accounted for only 5% of the domestic drug market, according to CMH data, none of the top 10 sales of single anti-drugs. At present, the domestic market has a total of 6 domestic single resistance, 10 imported single anti-drug approved for listing, the overall number of approved is relatively small. From the PDB database, the domestic mono-resistance is currently only metoxi single-resistance and nito-pearl mono-resistance is still in sale, in general, the current domestic single-resistance market is basically monopolized by imported products. It shows that the development of biological drugs, especially antibody drugs, is still in its infancy, and there is still a great space for development.
, Jiahe Bio has a high investment value from the research and development pipeline. However, jiayu bio in the next 3 years the most likely to be listed clinical Phase III products (GB221, GB242, GB222), similar research and development competition is very fierce, competitors. It also means that Jia and Bio have a hard time grabbing the first-time advantage, and the cakes they can grab when they go on the market are limited.
addition, another important factor in Connbel's investment in Jia and Bio is the clinical progression of its competitive PD-1 products. At present, the domestic Hengrui Pharmaceutical, Junshi Biological, Xinda Biological three enterprises anti-PD-1 single anti-production application has been included in the priority review. Therefore, the research and development progress is still in the clinical phase I jia and biological competition will be later than the previous three at least 3 years to go public, less competitive.A conclusion
In a word, Jiahe biological overall research and development pipeline layout is more complete, good progress, the next 3 years should be able to have products on the market to obtain income, is the domestic biopharmaceis field travel speed of the research and development enterprises, but also occupied the rapid development of biological drugs, domestic biological drugs are still in the initial stage of development of the world. However, its research and development pipeline progress is not particularly outstanding, the future of the market products more intense competition, can be divided into a smaller cake.
, however, it may be a wise move for Mr. Connbey, a shareholder, to invest in the fast-growing biopharmaceus, even though the gains it can get through Jia and Bio are limited. With global biopharmaceas sales of $202 billion in 2016, Evaluate Pharma predicts that biopharmaceus will continue to maintain a strong market position in the future, with market share expected to rise from 25 percent ($202 billion) in 2016 to 30 percent ($326 billion) in 2022, according to Evaluate Pharma. Among them, monoantic drugs are the fastest-growing class of biomedical drugs, according to Evaluate Pharma statistics, from 1997 to 2017, the global single-drug industry has maintained a relatively high speed, in 1997 single-drug sales of only $310 million, and by 2017 global sales reached 106.070 billion U.S. dollars. In contrast, China Health CMH data show that China's total plate of Chinese medicine is about 390 billion yuan, a growth rate of only 5.7%.
in the main business growth is slow, into the rapid development of emerging areas, Connbey this move is going well. Previously, the New Kang sector had previously worked | Sitting on more than a dozen billion-scale products, net profit increased by 61%... It is mentioned in this article that investing in Jia and Bio is an important part of the layout of the biopharmaceus industry and actively promoting the implementation of its biopharmaceus industry strategy, laying a solid foundation for its long-term development.
However, although the biopharmaceus field is in high business climate, but the competition is also very fierce, as a first-timer Kang Enbei if you want to get a big cake, only jia and biology this investment is not enough ... (New Kangjie)